Patents by Inventor Robert BOCKERMANN

Robert BOCKERMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE PROTEASE
    Publication number: 20260028608
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Application
    Filed: October 9, 2025
    Publication date: January 29, 2026
    Applicant: Hansa Biopharma AB
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • CONDITIONING REGIMEN FOR CELL TRANSPLANT
    Publication number: 20260021168
    Abstract: The present invention relates to a conditioning regimen for the transplant of a cell to a subject, optionally wherein the cell is a hematopoietic stem/progenitor cells (HSPC), a CAR cell or a platelet. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject by administration of a cell transplant, wherein said administration comprises the conditioning regimen of the invention.
    Type: Application
    Filed: May 12, 2023
    Publication date: January 22, 2026
    Applicant: Hansa Biopharma AB
    Inventors: Rupert HANDGRETINGER, Robert BOCKERMANN, Peter LANG, Claus-Philipp MAIER
  • Cysteine protease
    Patent number: 12460194
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: November 4, 2025
    Assignee: Hansa Biopharma AB
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • METHODS FOR ENHANCING ADOPTIVE CELL TRANSFER IMMUNOTHERAPIES
    Publication number: 20250325640
    Abstract: The present invention relates to methods for enhancing an adoptive cell transfer immunotherapy that targets an immunoglobulin light chain by administering a protein that has IgG cysteine protease or IgG endoglycosidase activity.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 23, 2025
    Applicant: Hansa Biopharma AB
    Inventors: Raghuveer RANGANATHAN, Robert BOCKERMANN, Anna-Karin ROBERTSON, Christian KJELLMAN, Gianpietro DOTTI
  • CYSTEINE PROTEASE
    Publication number: 20240360432
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Application
    Filed: May 18, 2021
    Publication date: October 31, 2024
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • CONDITIONING REGIMEN FOR TRANSPLANT
    Publication number: 20230210962
    Abstract: The present invention relates to a conditioning regimen for the transplant of a cell, tissue or organ, optionally hematopoietic stem / progenitor cells, to a subject. The invention also relates to methods for the induction of hematopoietic chimerism in a subject. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject, in which hematopoietic chimerism is induced in order to improve the benefit to the subject of a subsequent therapy. The subsequent therapy may be a cell, tissue or organ transplant or may a gene therapy administered using genetically modified hematopoietic stem cells/progenitor cells.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 6, 2023
    Applicant: Hansa Biopharma AB
    Inventors: Robert Bockermann, Anna-Karin Louise Robertson, Jiaxin LIN, Colin Charles ANDERSON
  • IMMUNOGLOBULIN DETECTION AND ASSOCIATED THERAPIES
    Publication number: 20230110085
    Abstract: The present invention relates to improved methods for detecting immunoglobulin M (IgM), immunoglobulin A (IgA) and immunoglobulin E (IgE) antibodies, and new therapies for diseases and conditions mediated by pathogenic antibodies and antibody complexes.
    Type: Application
    Filed: February 12, 2021
    Publication date: April 13, 2023
    Applicant: Hansa Biopharma AB
    Inventors: Anna RUNSTRÖM, Robert BOCKERMANN, Kristoffe SJÖHOLM, Markus ROUPÉ, Christian KJELLMAN, Tomas LORANT